The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | Targeting KRAS-driven NSCLC
Jia Luo, MD, Dana-Farber Cancer Institute, Boston, MA, discusses targeting KRAS mutations in non-small cell lung cancer (NSCLC), which has historically been an unfeasible endeavor despite their prevalence as oncogenic drivers. Now, there are multiple KRAS-targeted drugs being explored in early phase clinical trials for the treatment of KRAS-driven NSCLC. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
